AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03070184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise capacity VO2 max determination
Description: Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.
Study NCT03070184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized meals
Description: Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
Study NCT03070184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standardized meals
Description: Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
Study NCT03070184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise challenge
Description: Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.
Study NCT03070184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise challenge
Description: Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.
Study NCT03070184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate ER
Description: Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.
Study NCT03070184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate ER
Description: Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.
Study NCT03086915 — intervention group
Intervention type: DRUG
Intervention: Neuromuscular Blocking Agent
Description: Administration of neuromuscular blockers during anesthesia
Study NCT03410914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Application of hemopatch to the divided end of the pancreas during surgery.
Study NCT05506865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
Study NCT00002740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Study NCT00002740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00002740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00002740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00002740 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy
Study NCT00002740 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study NCT03514381 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Patients starting a treatment with Doxorubicin and Ifosfamide
Description: 9 blood samples will be collected at each Cycle:~* Cycle 1 (Day 1-Day 2-Day 3)~* Cycle 2 (Day 1-Day 2-Day 3)
Study NCT04264975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Description: Fecal microbiota transplantation (FMT) is the administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient's microbial composition and confer a health benefit
Study NCT00934700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xenon gas
Description: 30% Xenon gas inhaled for 24 hours
Study NCT01812798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Double Blind Placebo Controlled Food Challenge
Description: All participants will undergo Double Blind Placebo Controlled Food Challenge. Participants will be randomized to receive either Peanut on Day 1, Placebo on Day 2, or vice versa.~For 'Peanut' arm, participants will be fed increasing doses of peanut until mild objective allergic reaction is observed.~Doses will be increased every 20-30 minutes. All doses are listed in g peanut flour~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000~For Placebo arm, participants will be fed increasing amounts of food matrix without peanut flour.
Study NCT01812798 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Double Blind Placebo Controlled Food Challenge
Description: All participants will undergo Double Blind Placebo Controlled Food Challenge. Participants will be randomized to receive either Peanut on Day 1, Placebo on Day 2, or vice versa.~For 'Peanut' arm, participants will be fed increasing doses of peanut until mild objective allergic reaction is observed.~Doses will be increased every 20-30 minutes. All doses are listed in g peanut flour~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000~For Placebo arm, participants will be fed increasing amounts of food matrix without peanut flour.
Study NCT01530893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavanone - supplement
Description: acute single optimal dose
Study NCT01530893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanone - food
Description: acute single dose
Study NCT01530893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanone - placebo
Description: acute single dose (flavanone free)
Study NCT01530893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isoflavone - supplement
Description: acute single optimal dose
Study NCT01530893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isoflavone - food
Description: acute single optimal dose
Study NCT01530893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isoflavone - placebo
Description: acute single dose (isoflavone free)
Study NCT01530893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isoflavone - metabolite supplement
Description: acute single optimal dose of commercial product
Study NCT01530893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavan-3-ol - supplement
Description: acute single optimal dose
Study NCT01530893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavan-3-ol - food
Description: acute single optimal dose
Study NCT01530893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavan-3-ol - placebo
Description: acute single dose (flavan-3-ol free)
Study NCT01530893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanin - supplement
Description: acute single optimal dose
Study NCT05506865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
Study NCT00179348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00179348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00179348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Undergo a yoga-based rehabilitation program
Study NCT00179348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Undergo a yoga-based rehabilitation program
Study NCT02972450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 MG [Entyvio]
Description: Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline.
Study NCT02972450 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for MVA it is a solution composed of S08 buffer (as for the MVA vaccine) that will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection.~Placebo for GTU-MultiHIV B-clade vaccine: Sodium Chloride (NaCl) for infusion, 0.9%.~Placebo for Vedolizumab: Sodium Chloride (NaCl) for infusion, 0.9% in 250 ml infusion bags.
Study NCT03366961 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conversion surgery
Description: Palliative chemotherapy followed by radical gastrectomy
Study NCT01630954 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suction and evacuation
Description: In single evacuation group women will be treated by suction evacuation and curettage is performed at the end of evacuation in one sitting. An ultrasound will be done later to examine completeness of evacuation. If there is significant amount of residual molar tissue or persistence of heavy bleeding a repeat curettage will be done . Women will be followed up with serum beta hcg 1 week after the evacuation and then weekly till the titer is negative. After three consecutive negative titre beat HCG estimation will be done at two weekly interval.
Study NCT01630954 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suction and evacuation
Description: In double evacuation group , women will be treated by suction evacuation and a thorough curettage will be avoided. A second evacuation with thorough curettage will be performed after 5 - 7 days of first evacuation.
Study NCT02046278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeSeal™ Kit
Study NCT01892904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EE20/DRSP(BAY86-5300)
Description: One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
Study NCT01892904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP(BAY86-5300)
Description: One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
Study NCT02159885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Study NCT01873157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11.
Study NCT01873157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11.
Study NCT00618124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248; Capecitabine
Description: Dose finding study using SU011248 daily by oral capsule in a continuous regimen or administered for 4 out of every 6 weeks (Schedule 4/2) or 2 out of every 3 weeks (Schedule 2/1), with capecitabine administered 2 out of every 3 weeks until progression or unacceptable toxicity.
Study NCT03102008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Emotional Disorders in Adolescents (UP-A)
Description: The Unified Protocol for Emotional Disorders in Adolescents (UP-A), is a transdiagnostic therapeutic intervention employing core dysfunction approaches, defined as such due to their attendance to features of various (emotional) disorders. The treatment may work to ameliorate symptoms more broadly by targeting cross-cutting features common to the range of disorders targeted. Specifically, the UP-A might lead to the successful treatment of an array of emotional disorders in youth by targeting processes common across these frequently co-occurring problems including poor distress tolerance, limited cognitive flexibility, and heightened avoidance.
Study NCT01422707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 10 mg/m2/per day PO at bedtime (X4 weeks)
Study NCT03341494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Gefitinib 250mg Thalidomide 200 MG
Study NCT03341494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Gefitinib 250mg Thalidomide 200 MG
Study NCT03433300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ottobock Kenevo/C-Leg
Description: Microprocessor-controlled prosthetic knee
Study NCT03433300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ottobock 3R60/3R62
Description: Nonmicroprocessor-controlled knee
Study NCT02195596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise+strength
Description: The program consist in a Continuous High aerobic exercise and moderate intensity intervals (ShoshanaB et al, 2012) combined with muscular strength exercises and joint mobility. Patients come three times a week for six months to the primary health center and will be supervised by an expert nurse.
Study NCT02195596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity aerobic exercise+strength
Description: Low intensity aerobic exercise+strength program is similar to the other intervention but differs in the intensity of the exercise as it works with intensities below 40% of heart rate reserve.~--------------------------------------------------------------------------------
Study NCT02412878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered as an IV infusion
Study NCT02412878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Commercially available dexamethasone was obtained by the investigational site.
Study NCT03038776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant influenza hemagglutinin
Description: Avian H7N9 influenza vaccine
Study NCT01530893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anthocyanin - food
Description: acute single optimal dose
Study NCT01530893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anthocyanin - placebo
Description: acute single dose (anthocyanin free)
Study NCT03616795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: Administered orally
Study NCT03616795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3154207
Description: Administered orally
Study NCT00556647 — intervention group
Intervention type: PROCEDURE
Intervention: fast track diagnosis
Description: fast-track diagnosis, PET-CT, bronchoscopy
Study NCT00556647 — intervention group
Intervention type: PROCEDURE
Intervention: conventional diagnosis
Description: out-patient diagnosis
Study NCT02413814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anger Reduction Treatment
Description: Eight 30-minute sessions of interpretation modification to reduce angry interpretation biases.
Study NCT02413814 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: Eight 30-minute sessions of informative videos on healthy living and relaxation videos.
Study NCT02780960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPV self-testing
Description: Patients will perform HPV testing themselves at home.
Study NCT03055494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 was followed by monthly dosing up to Week 48
Study NCT03055494 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
Study NCT02102594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
Study NCT02000882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT02000882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT02000882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT03073356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of 3-OHB
Description: Increase in 3-OHB levels
Study NCT01227616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: IV Ferumoxytol
Study NCT01227616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose
Description: IV Iron Sucrose
Study NCT04328103 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Behavior Therapy (CBT)
Description: Following established procedures at the DES at NYSPI, 12 sessions of individual manual-driven CBT (Emery, 2000) will be conducted by highly trained master degree clinicians.
Study NCT04328103 — intervention group
Intervention type: BEHAVIORAL
Intervention: Nonspecific Supportive Therapy (PBO)
Description: As a non-CBT intervention that includes warmth, genuineness and empathy (Linde et al., 2011), nonspecific supportive therapy (PBO) will be administered in a parallel format to CBT, also consisting of 12 individual sessions.
Study NCT00920647 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: 3 dose cohorts were planned. Within each dose cohort, patients will be randomized to 1 of 2 treatment options: treatment with study drug or no treatment with 4 treated patients per dose group and a total of 4 untreated patients (1-2 untreated patients will be assigned in each dose cohort). They will not undergo surgical placement of an Intrathecal Drug Delivery Device (IDDD), and will not receive Idursulfase-IT.
Study NCT00920647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idursulfase IT (1 mg)
Description: The original design of the study was to test the dose levels of 10, 30 and 100 mg. This was based on a calculation of a minimally effective dose around 10 mg, with subsequent dose levels being chosen as increasing half-log steps. During the conduct of the study; however, it became clear that the 10 mg dose elicited a strong Pharmacodynamic response, as measured by a dramatic and sustained drop in the CSF GAG levels. This indicated the need to explore a lower level as a minimally effective dose level, leading to the introduction of the 1 mg group. Enrollment of patients in this dose cohort will commence after the last patient has been enrolled in 30 mg dose cohort. 4 patients will be undergo surgical placement of an IDDD and receive 1 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
Study NCT00920647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idursulfase IT (10 mg)
Description: Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 10 mg idursulfase-IT as an intrathecal (IT) injection via an IDDD once per month (ie, every 28 days) for 6 month.
Study NCT00920647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idursulfase IT (30 mg)
Description: Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 30 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
Study NCT03128671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAVoR Intervention
Description: The FAVoR intervention includes a set of 8 scripted recorded messages, no longer than 2 minutes long, includes subject's name, uses simple terms, and is written at a 5th grade reading level. Messages include information about the critical care environment, the visual and auditory stimuli to be expected, and the availability of providers and family.
Study NCT00865852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl 750 mg Extender Release tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under non-fasting conditions
Study NCT00865852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLUCOPHAGE® XR 750 mg tablets, single dose
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
Study NCT00723385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 or 2000 IU/day)
Description: Dose titration beginning with 1000 IU/day and either remaining at 1000 IU/day for weeks 7-12 if normalized D levels at 6 weeks or increasing to 2000 IU/day for weeks 7-12 if levels not normalized at week 6
Study NCT00723385 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo for 12 weeks with repeated D measurements
Study NCT04687098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Idarubicin
Description: 12 mg/m2/day; intravenous, administration at induction phase, days 1 to 3.
Study NCT04687098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ara-C
Description: 200mg/m2/day, intravenous at induction phase; days 1-7.~- High dose during consolidation phase. In patients up to 60 years 3g/m2/12hours days 1,3,5, and patients 60 to 70 years: 1.5g/m2/12hours days 1,3,5.
Study NCT04687098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF
Description: * Administration at induction phase to remission days 1 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatment arises 30x10e9/L.~* Administration at consolidation phase day 7.
Study NCT04687098 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic matched or unrelated donor transplant.
Description: To be performed in patients in the intermediate or adverse risk groups.